Table 6 Overall survival, progression free survival and malignant progression free survival at 3, 5 and 10 years after surgery in patients with total resection, stratified according to molecular diagnosis (WHO 2016).
From: Multimodal integrated approaches in low grade glioma surgery
Among patients with EOR = 100% % (95% CI) | |||
|---|---|---|---|
DA IDHwt | DA IDHmt | OA IDHmt 1p19q cod | |
Number of patients | 12 | 45 | 37 |
Overall survival %(95%CI) | |||
3 years | 91.67 (53.90–98.78) | 97.56 (83.92–99.65) | 100.00 (-) |
5 years | 91.67 (53.90–98.78) | 91.76 (76.39–97.29) | 100.00 (-) |
10 years | 91.67 (53.90–98.78) | 87.59 (69.47–95.29) | 86.54 (55.83–96.48) |
Progression free survival %(95%CI) | |||
3 years | 91.67 (53.90–98.78) | 88.15 (73.83–94.89) | 93.94 (77.69–98.47) |
5 years | 82.50 (46.09–95.33) | 62.40 (43.68–76.45) | 77.18 (55.45–89.25) |
10 years | 68.75 (29.07–89.26) | 51.51 (30.79–68.82) | 26.23 (7.52–50.06) |
Malignant progression free survival %(95%CI) | |||
3 years | 91.67 (53.90–98.78) | 92.85 (79.43–97.64) | 96.67 (78.61–99.52) |
5 years | 91.67 (53.90–98.78) | 85.97 (68.99–94.03) | 96.67 (78.61–99.52) |
10 years | 91.67 (53.90–98.78) | 71.05 (42.29–87.30) | 70.86 (41.90–87.25) |
